PO.TB10.05 · 肿瘤生物学
研究遗传背景对TNBC类器官和共培养中TNBC-T细胞相互作用的影响
Investigating the influence of genetic background on TNBC-T cell interactions in TNBC organoids and co-cultures
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
三阴性乳腺癌(TNBC)是一种侵袭性的乳腺癌(BC)形式,以早期复发和预后不良为特征。TNBC的死亡负担在不同遗传祖源的人群中分布不均,非洲裔人群显示出更高的TNBC发病率和高死亡率。肿瘤微环境(TME)在TNBC发展中起关键作用。TME不同组分(如T细胞)之间的相互作用可调节TNBC进展和对治疗的耐药性。此外,TME可能促成在欧洲裔(EA)与非洲裔TNBC患者之间观察到的结局差异。然而,介导非洲裔女性TNBC免疫逃逸的免疫调节机制仍研究不足。为研究这些机制,我们从非裔美国人和加纳裔TNBC患者中构建了类器官。将来自EA、AA和GH患者的TNBC肿瘤植入免疫抑制小鼠,并从这些组织建立PDX来源类器官(PDXos)。使用多重免疫荧光(IF)和qRT-PCR评估PDXos及配对PDX和原代组织中上皮、间充质、基质和免疫标志物的表达。从健康对照PBMC中分离T细胞并按先前发表的方案进行活化。将5种不同的TNBC类器官(包括1例EA、2例AA和2例GH PDxOs)与T细胞共培养,随后使用流式细胞术分析评估类器官对T细胞的应答性。最后,将免疫耐受类器官与T细胞共培养,然后分选用于下游分析。我们成功从不同遗传祖源的患者中建立了8种TNBC类器官(PDxOs),包括1例EA TNBC、3例GH TNBC和5例AA TNBC。多重IF和qRT-PCR分析显示,所获得的PDXos保留了其来源组织的上皮(EpCAM)和间充质(vimentin)特征。与T细胞共培养显示,类器官呈现出不同的免疫应答模式,并对T细胞耗竭和活化产生不同的影响。流式细胞术分析显示,上皮性TNBC类器官对T细胞更具应答性,而间充质样类器官更具免疫耐受性。对与T细胞共培养生长的类器官进行qRT-PCR分析显示,其vimentin表达增加,提示EMT在这些类器官的免疫逃逸中发挥作用。这些发现揭示,PDXos重现了其来源组织的上皮和间充质模式,是研究非洲裔TNBC患者中祖源特异性免疫应答和耐受通路的宝贵平台。
查看英文原文 English abstract
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer (BC) characterized by early relapse and poor prognosis. The TNBC mortality burden is unequally distributed among populations of different genetic ancestry, with populations of African descent displaying higher incidence of TNBC with high mortality rates. The tumor microenvironment (TME) plays a key role in TNBC development. Interactions between different TME components, such as T cells, can modulate TNBC progression and resistance to therapies. Additionally, the TME can contribute to the disparities in outcomes observed between TNBC patients of EA versus African ancestry. However, the immunomodulatory mechanisms that mediate immune evasion in TNBC in women of African descent remain understudied. To investigate these mechanisms, we developed organoids from TNBC patients of African American and Ghanian ancestry. TNBC tumors from EA, AA and GH patients were implanted into immunosuppressed mice and PDX-derived organoids (PDXos) were established from these tissues. The expression of epithelial, mesenchymal, stromal and immune markers in PDXos and matching PDXs and primary tissues was assessed using multiplex IF and qRT-PCR. T cells were isolated from healthy control PBMCs and activated as per previously published protocols. 5 different TNBC organoids, including 1 EA, 2 AA and 2 GH PDxOs, were co-cultured with T cells, following which the responsiveness of organoids to T cells was assessed using flow cytometric analysis. Finally, immune-resistant organoids were co-cultured with T cells then sorted for downstream analysis. We have successfully established 8 TNBC organoids (PDxOs) from patients of different genetic ancestries, including 1 EA TNBCs, 3 GH TNBCs and 5 AA TNBCs. Multiplex IF and qRT-PCR analysis revealed that the obtained PDXos retained the epithelial (EpCAM) and mesenchymal (vimentin) signatures of their tissues of origin. Co-culture with T cells revealed that the organoids displayed differing patterns of immune responsiveness and exerted distinct effects on T cell exhaustion and activation. Flow cytometric analysis showed that epithelial TNBC organoids were more responsive to T cells whereas mesenchymal-like organoids were more immune resistant. qRT-PCR analysis of organoids grown in co-culture with T cells revealed that they had increased vimentin expression, suggesting a role for EMT in immune evasion in these organoids. These findings reveal that PDXos recapitulate the epithelial and mesenchymal patterns of their tissues of origin and represent a valuable platform for investigating ancestry-specific pathways of immune responsiveness and resistance in TNBC patients of African ancestry.
利益披露 Disclosure
B. Farran, None..
M. Kamita, None..
S. Wong, None.
S. Antwi,
Pfizer ).
Genentech ).
V. Aboah, None..
H. Larrious-Lartey, None..
J. Jessica Bensenhaver, None..
A. Haythem, None..
W. Eleonor, None.
F. Amponsah,
Pfizer ).
J. Nsafu.,
Pfizer ).
R. Dampson, None.
P. Akapko,
Pfizer ).
E. Jiage,
Pfizer ).
Genentech ).